Literature DB >> 29277385

Outcomes of resection for solitary ≤5 cm intrahepatic cholangiocarcinoma.

Paola Tarchi1, Parissa Tabrizian2, Jake Prigoff1, Myron Schwartz1.   

Abstract

BACKGROUND: Resection remains the treatment of choice achieving 5-year survival rates of 22% to 40%. The aim of this analysis was to examine the outcomes of patients with solitary ≤5 cm intrahepatic cholangiocarcinoma.
METHODS: A retrospective chart review was performed on 123 patients undergoing resection for primary intrahepatic cholangiocarcinoma from 1995 to 2013. Group 1 included patients with asymptomatic solitary intrahepatic cholangiocarcinoma measuring ≤5 cm.
RESULTS: Group 1 (n = 33, 27%) had a greater rate of underlying liver disease, cirrhosis, minor resection, favorable pathologic features including decreased rate of perineural invasion, vascular invasion, lymph node involvement, and satellite nodules (P < .05). Factors associated with overall poor outcome were patients in Group 2 (P=.025), positive margin (P=.04), presence of satellite nodules (P = .008), and multinodularity (P=.058). Factors associated with recurrence in Group 1 were presence of satellite nodules (P=.004), and tumor size ≥4 cm (P=.031). Factors associated with decreased survival in Group 1 was transfusion requirement (P = 0.018). The 5-year recurrence and survival rates were (39% vs 67%) and (71% vs 53%) in Group 1 versus Group 2, respectively (P=.111).
CONCLUSION: Resection of solitary intrahepatic cholangiocarcinoma ≤5 cm can achieve 5-year survival rates up to 71%. Results were comparable to those of patients undergoing transplantation for hepatocellular cancer within the Milan criteria.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29277385     DOI: 10.1016/j.surg.2017.09.058

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  7 in total

1.  Machine learning radiomics can predict early liver recurrence after resection of intrahepatic cholangiocarcinoma.

Authors:  Joshua S Jolissaint; Tiegong Wang; Kevin C Soares; Joanne F Chou; Mithat Gönen; Linda M Pak; Thomas Boerner; Richard K G Do; Vinod P Balachandran; Michael I D'Angelica; Jeffrey A Drebin; T P Kingham; Alice C Wei; William R Jarnagin; Jayasree Chakraborty
Journal:  HPB (Oxford)       Date:  2022-02-17       Impact factor: 3.842

2.  Reappraisal of the T Category for Solitary Intrahepatic Cholangiocarcinoma by Tumor Size in 611 Early-Stage (T1-2N0M0) Patients After Hepatectomy: a Surveillance, Epidemiology, and End Results (SEER) Analysis.

Authors:  YiPing Chen; ShanGeng Weng
Journal:  J Gastrointest Surg       Date:  2020-11-02       Impact factor: 3.452

Review 3.  Resection for intrahepatic cholangiocellular cancer: new advances.

Authors:  Daniel R Waisberg; Rafael S Pinheiro; Lucas S Nacif; Vinicius Rocha-Santos; Rodrigo B Martino; Rubens M Arantes; Liliana Ducatti; Quirino Lai; Wellington Andraus; Luiz C D'Albuquerque
Journal:  Transl Gastroenterol Hepatol       Date:  2018-09-12

4.  Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells.

Authors:  Koh Kitagawa; Kei Moriya; Kosuke Kaji; Soichiro Saikawa; Shinya Sato; Norihisa Nishimura; Tadashi Namisaki; Takemi Akahane; Akira Mitoro; Hitoshi Yoshiji
Journal:  Int J Mol Sci       Date:  2020-10-14       Impact factor: 5.923

5.  Aggressive local treatment for recurrent intrahepatic cholangiocarcinoma-Stereotactic radiofrequency ablation as a valuable addition to hepatic resection.

Authors:  Eva Braunwarth; Peter Schullian; Moritz Kummann; Simon Reider; Daniel Putzer; Florian Primavesi; Stefan Stättner; Dietmar Öfner; Reto Bale
Journal:  PLoS One       Date:  2022-01-04       Impact factor: 3.240

6.  Radiomics Analysis of Contrast-Enhanced CT for the Preoperative Prediction of Microvascular Invasion in Mass-Forming Intrahepatic Cholangiocarcinoma.

Authors:  Fei Xiang; Shumei Wei; Xingyu Liu; Xiaoyuan Liang; Lili Yang; Sheng Yan
Journal:  Front Oncol       Date:  2021-11-19       Impact factor: 6.244

7.  Impact of cirrhosis on long-term survival outcomes of patients with intrahepatic cholangiocarcinoma.

Authors:  Jian Wang; Yiwen Qiu; Yi Yang; Shu Shen; Ming Zhi; Bo Zhang; Wentao Wang
Journal:  Cancer Med       Date:  2022-04-12       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.